Shall We Consider DPP-4-Inhibitors as Cardiovascular Safe Drugs?
نویسندگان
چکیده
منابع مشابه
DPP-4 Inhibitors
The first dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin was approved in 2006 as treatment for diabetes concurrently with lifestyle changes. A combined product of sitagliptin and glucophage was approved by the U.S. Food and Drug Administration in 2007. The second DPP-4 inhibitor, saxagliptin, was approved in theU.S. It was approved both as monotherapy as well as in combination with metform...
متن کاملPain in leprosy patients: shall we always consider as a neural damage?
Neuropathy is the hallmark of leprosy, with Mycobacterium leprae affecting primarily skin and peripheral nerves, which results in an immunological response and leads to motor, sensory and autonomic alterations. Neuropathic pain is a common complaint due to leprosy neuritis, whether spontaneous or on palpation of a nerve trunk. It can be present during or after treatment with multidrug therapy, ...
متن کاملDPP-4 inhibitors-renoprotection in diabetic nephropathy?
There is no doubt that rates of chronic kidney disease are escalating and that this rise is the main contributor to the increasing prevalence of diabetic nephropathy. It is also clear that the increase in kidney failure continues despite tight blood glucose and blood pressure control, as well as renin-angiotensin system blockade. In response, research into novel therapies to treat diabetic neph...
متن کاملDPP 4 (dipeptidylpeptidase-4) inhibitors: beyond glycemic control
Type 2 diabetes is characterized by impaired insulin release from β-cell of pancreas and insulin resistance. Different classes of hypoglycemic drugs are available with different mechanism of action with nearly equipotent efficacy. GLP-1(glucagon like peptide-1) analogue and DPP 4 inhibitors are new developed molecules for the management of diabetes. They act via glucose dependent insulin releas...
متن کاملClinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
INTRODUCTION Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral antidiabetic agents for the treatment of type 2 diabetes mellitus, which lower blood glucose without causing severe hypoglycemia. However, the first cardiovascular (CV) safety trials have only recently reported their results, and our understanding of these therapies remains incomplete. Using clinical trial simulations, w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes Case Reports
سال: 2017
ISSN: 2572-5629
DOI: 10.4172/2572-5629.1000111